{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000007","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.198521+00:00","generated_at":"2026-06-05T16:54:18.398146+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere and CSL Vifor receive CHMP positive opinion for sparsentan in IgAN in EU","bullets":["EMA CHMP recommended conditional marketing authorization for sparsentan for primary IgAN with proteinuria >1.0 g/day.","Positive opinion based on Phase 3 PROTECT Study results; EC final decision pending.","If approved, sparsentan would get CMA in all EU member states plus Iceland, Liechtenstein, Norway.","Already marketed in US as FILSPARI under accelerated approval for proteinuria reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000007","json":"https://secwatch.observer/filing/0001438533-24-000007.json","markdown":"https://secwatch.observer/filing/0001438533-24-000007.md","text":"https://secwatch.observer/filing/0001438533-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/0001438533-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/tvtx-20240223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:54:18.398146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}